PRESS RELEASE published on 07/03/2024 at 08:12, 1 year 8 months ago CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac initiates strategic restructuring to focus on high-value mRNA pipeline opportunities, including workforce reduction and new GSK agreement Oncology Strategic Restructuring CureVac MRNA Pipeline GSK Agreement
PRESS RELEASE published on 07/03/2024 at 08:09, 1 year 8 months ago GSK and CureVac to Restructure Collaboration into New Licensing Agreement GSK and CureVac restructure collaboration into new licensing agreement for mRNA vaccines development, manufacturing, and commercialization globally Licensing Agreement Collaboration GSK MRNA Vaccines CureVac
BRIEF published on 06/24/2024 at 22:10, 1 year 8 months ago CureVac Announces Voting Results of General Meeting Annual General Meeting Voting Results Board Appointments CureVac MRNA
PRESS RELEASE published on 06/24/2024 at 22:05, 1 year 8 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of the general meeting, including board appointments and auditor reappointment. Shareholders voted in favor of all proposals Appointments Voting Results General Meeting CureVac Auditor Reappointment
BRIEF published on 05/28/2024 at 13:05, 1 year 9 months ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
PRESS RELEASE published on 05/28/2024 at 13:00, 1 year 9 months ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 1 year 9 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
PRESS RELEASE published on 05/23/2024 at 13:00, 1 year 9 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 1 year 10 months ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:08, 1 year 10 months ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
Published on 03/17/2026 at 13:30, 1 hour 12 minutes ago Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 13:30, 1 hour 12 minutes ago Namibia Critical Metals Welcomes Toyota Tsusho as Strategic Partner in the Lofdal Heavy Rare Earths Project
Published on 03/17/2026 at 13:00, 1 hour 42 minutes ago Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Published on 03/17/2026 at 13:00, 1 hour 42 minutes ago High-Resolution Airborne Survey Completed at Music Valley HREE Project
Published on 03/17/2026 at 12:30, 2 hours 12 minutes ago Revival Gold Targets Underground Resource Growth With Drilling at Beartrack-Arnett Gold Project in Idaho
Published on 03/17/2026 at 14:15, 26 minutes ago thyssenkrupp nucera to Conduct FEED Study for 260 MW Green Hydrogen Project in India
Published on 03/17/2026 at 14:05, 37 minutes ago TUMI UNVEILS THE "MEDITERRANEAN ESCAPE" CELEBRATING THE ALLURE OF THE COAST AND THE EASE OF TRAVEL
Published on 03/17/2026 at 14:00, 42 minutes ago Nebius gives VC-backed growth-stage companies a fast track to enterprise adoption in collaboration with NVIDIA
Published on 03/17/2026 at 13:53, 48 minutes ago EQS-Adhoc: thyssenkrupp nucera Signs Contract for FEED Study for 260 MW Green Hydrogen Project in India
Published on 03/17/2026 at 13:43, 58 minutes ago European customer orders CEOTRONICS products worth approx. €1.8 million
Published on 03/17/2026 at 07:00, 7 hours 42 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 20 hours 42 minutes ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 20 hours 44 minutes ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 20 hours 45 minutes ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
